Although the estimated dose to tumor was sufficient for clinical applications and that absorbed dose by dose-limiting organs was below values measure for 225Ac-PSMA-617, the therapeutic efficacy of 213Bi-PSMA-617 appeared to be significantly lower than with the 225Ac-labeled analogue [181]. This evidence concerns the gene FOLH1 and neoplasm.